人才建设

您所在的位置: 首页 - 人才建设 - 师资队伍 - 准聘长聘教师 - 教授 - 阜外医院

阜外医院

个人简介

杨跃进,1958年生,籍贯江苏靖江,心血管病和冠心病介入治疗专家,阜外医院主任医师,博士生导师。1978-1982年毕业于苏州医学院医学系,学士学位。1984-1989年在中国协和医大研究生院心血管病专业攻读硕、博士学位,从事急性心梗心功能测定、心室重构和心衰防治研究。1993和1996年分别在协和医大破格晋升为副和正主任医师;1998年获博导资格;2000年享受国务院特贴。2002-2019年任副院长;2015-2019年任国家心脏中心副主任;兼任过心内科及介入、心衰(创建)和冠心病三大中心主任。


主要研究方向

冠心病复杂、高危患者和病变微创介入技术难题攻克;探索中药通心络对急性心肌梗死微血管屏障功能保护,心肌无复流和机械并发症的防治及机制;能提高治疗急性心梗效果的骨髓干细胞及其外泌体新一代种子研发。


代表性成果

1. Xu JY#, Xiong YY, Tang RJ, Jiang WY, Ning Y, Gong ZT, Huang PS, Chen GH, Xu J, Wu CX, Hu MJ, Xu J, Xu Y, Huang CR, Jin C, Lu XT, Qian HY, Li XD, Yang YJ*. Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction. Cardiovasc Res. 2022 Jul 20;118(9):2165-2178. (IF=13.081)

2Xiong Y#, Tang R, Xu J, Jiang W, Gong Z, Zhang L, Ning Y, Huang P, Xu J, Chen G, Li X, Hu M, Xu J, Wu C, Jin C, Li X, Qian H, Yang Y*. Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway. Stem Cell Res Ther. 2022 Jul 7;13(1):289. (IF=8.096)

3. Cui K#, Fu R#, Yang J, Xu H, Yin D, Song W, Wang H, Zhu C, Feng L, Wang Z, Wang Q, Lu Y, Dou K*, Yang Y*. Admission Blood Glucose and 2-Year Mortality After Acute Myocardial Infarction in Patients With Different Glucose Metabolism Status: A Prospective, Nationwide, and Multicenter Registry. Front Endocrinol (Lausanne). 2022 Jun 15;13:898384. (IF=6.055)

4. Huang P#, Wang L, Li Q, Tian X, Xu J, Xu J, Xiong Y, Chen G, Qian H, Jin C, Yu Y, Cheng K, Qian L*, Yang Y*. Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. Cardiovasc Res. 2020 Feb 1;116(2):353-367. (IF=13.081)

5Xu H#, Yang Y*, Wang C, Yang JLi W, Zhang X, Ye Y, Dong Q, Fu R, Sun H, Yan XGao X, Wang Y, Jia X, Sun Y, Wu Y, Zhang J, Zhao W, Sabatine MS, Wiviott SD, for CAMI registry investigators. Association of hospital-level differences in care with outcomes among patients with acute ST-Segment elevation myocardial infarction in China. JAMA Network open. 2020;3(10):e2021677. (IF=11.64)

6Chen G#, Xu C, Gillette TG, Huang T, Huang P, Li Q, Li X, Li Q, Ning Y, Tang R, Huang C, Xiong Y, Tian X, Xu J, Xu J, Chang L, Wei C, Jin C, Hill JA*, Yang Y*. Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury. Theranostics. 2020 Sep 23;10(25):11754-11774.  (IF=11.600)

7. Xu J#, Xiong YY, Li Q, Hu MJ, Huang PS, Xu JY, Tian XQ, Jin C, Liu JD, Qian L*, Yang YJ*. Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction. Stem Cells Transl Med. 2019 Oct;8(10):1068-1083. (IF=7.655)

8Xu B#, Redfors B*, Yang Y*, Qiao S, Wu Y, Chen J, Liu H, Chen J, Xu L, Zhao Y, Guan C, Gao R, Généreux P. Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2016 Oct 24;9(20):2086-2093. (IF=11.075)

9. Yang YJ#*, Kandzari DE, Gao Z, Xu B, Chen JL, Qiao SB, Li JJ, Qin XW, Yao M, Wu YJ, Yuan JQ, Chen J, Liu HB, Dai J, Chen T, Wang Y, Li W, Gao RL. Transradial versus transfemoral method of percutaneous coronary revascularization for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes. JACC Cardiovasc Interv. 2010 Oct;3(10):1035-42.  (IF=11.075)

10. Yang YJ#*, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, Yang GS, Li JJ, Shen R, He ZX, Lu MJ, Zhao SH. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J. 2008 Jun;29(12):1578-90. (IF=35.855)